Search Results 351-360 of 17471 for Metformin
- Use of anti-obesity medications upon screening (i.e., orlistat, phentermine-topiramate, liraglutide, semaglutide, bupropion-naltrexone), metformin or GLP-1 ...
Pioglitazone (oral route) · Pioglitazone and glimepiride (oral route) · Pioglitazone and metformin (oral route) · Piperacillin and tazobactam (intravenous route).
... metformin, acarbose or DPP-4 inhibitors (e.g. sitagliptin and vildagliptin). Past or current history of pancreatitis, gallstones, history of alcoholism ...
Metformin. Show More. Using this medicine with any of the following medicines may cause an increased risk of certain side effects, but using both drugs may be ...
... metformin dose and maintain glycemic control); Previous treatment with ranolazine for > 7 consecutive days within 30 days prior to Randomization, or known ...
Participation eligibility · Concurrent use of any non-insulin glucose-lowering agent other than metformin (including GLP-1 agonists, Symlin, DPP-4 inhibitors, ...
Insulin Glulisine; Insulin Lispro, Recombinant; Linagliptin; Liraglutide; Lixisenatide; Magnesium Sulfate; Metformin; Miglitol; Nateglinide; Pioglitazone ...
No exposure to metformin; Prednisone dose > 15mg per day within 7 days of blood draw. Participating Mayo Clinic locations. Study statuses change often. Please ...
Walther-Antonio is studying the microbiome impact in ovarian cancer recurrence with and without adjuvant metformin treatment in a clinical trial and patient- ...
Use of any glucose-lowering agents including metformin or sulfonylureas. For female subjects: positive pregnancy test at the time of enrollment or study ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your donation powers the future of medicine and helps save lives.